上海医药发布半年度业绩，归母净利润44.59亿元，同比增长51.56%

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) reported a revenue of 141.593 billion yuan for the first half of 2025, reflecting a year-on-year growth of 1.56% [1] - The company's net profit attributable to shareholders reached 4.459 billion yuan, marking a significant year-on-year increase of 51.56% [1] - However, the company's net profit excluding non-recurring items was 2.1 billion yuan, which represents a year-on-year decline of 22.38% [1] - Basic earnings per share stood at 1.20 yuan [1] Financial Performance - Revenue for the period was 141.593 billion yuan, up 1.56% year-on-year [1] - Net profit attributable to shareholders was 4.459 billion yuan, up 51.56% year-on-year [1] - Net profit excluding non-recurring items was 2.1 billion yuan, down 22.38% year-on-year [1] - Basic earnings per share were reported at 1.20 yuan [1]